Medtech gears up for a vintage acquisition year
Device deal making is back in a big way, despite the munificence of venture funds.
Medtech venture backers go in early
A sudden increase in seed and series A funding bodes well for the year ahead.
Invitae borrows against the future
Cancer diagnosis is likely to see a huge resurgence in demand as the pandemic ebbs, and Invitae wants to be ready.
Medtechs rake in the venture cash
In terms of private investments, 2020 was the year of the liquid biopsy.
